Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Metabolic & Weight

Survodutide

BI 456906

GLP-1/glucagon dual agonist

This Survodutide entry draws on 33 cited sources published 2024 to 2026. The evidence available is graded Phase 3 on this site's scale. Dosing is reported as described in the literature rather than as guidance. Sources checked .

At a glance

Class
GLP-1/glucagon dual agonist
Drug class
Metabolic & Weight
Structure
Long-acting dual agonist peptide
Route
SC injection
Half-life
Long-acting weekly
Evidence tier
Phase 3
Availability
Investigational
Research depth
126 indexed citations (PubMed 73 · CT 30 · EPMC 23) →

Mechanism of action

Dual GLP-1/glucagon receptor activation

Reported areas of research

Weight loss ~19%; MASH/NAFLD resolution Phase 2

Items above describe areas studied in published peptide literature, not approved indications. Most peptides catalogued here are not FDA-approved for human use.

Dosage protocols reported in literature

0.6-4.8 mg SC weekly

Reported research dosing only. This is not a clinical recommendation. Consult a qualified clinician before any human use.

Known concerns and limitations

GI side effects; injection reactions

Compared with

Survodutide has published head-to-head comparisons with 8 compounds that share its pharmacological class: mechanism, half-life, reported research dosing, evidence tier and regulatory status side by side.

Frequently asked questions

What dosing is reported for Survodutide in research literature?

Published peptide research reports the following dosing approach for Survodutide: 0.6-4.8 mg SC weekly. This is a research reference, not a clinical recommendation.

How is Survodutide administered in research?

Survodutide is administered via the following routes in published studies: SC injection.

What is the reported half-life of Survodutide?

No measured half-life for Survodutide is reported in the literature catalogued here. The catalog describes it as: Long-acting weekly.

Is Survodutide FDA-approved?

No. Survodutide is not an FDA-approved drug. PeptideHelper.org catalog status: Investigational.

What level of evidence supports Survodutide?

The current evidence base for Survodutide is best characterised as: Phase 3. See the methodology page for the full evidence-tier rubric.

What side effects are reported for Survodutide?

Known concerns reported in the literature for Survodutide include: GI side effects; injection reactions. Always consult a qualified clinician before any human use.

Is there anyone who should not use Survodutide?

No formal contraindications are established for Survodutide, because it is not an FDA-approved medicine and no approved label exists to define them. That is an absence of regulatory review rather than evidence of safety. Reported concerns from the literature are: GI side effects; injection reactions. Always consult a qualified clinician before any human use.

How does Survodutide work?

The mechanism of action reported for Survodutide in the literature: Dual GLP-1/glucagon receptor activation.

What is Survodutide studied for?

Survodutide has been studied in the published literature for: Weight loss ~19%; MASH/NAFLD resolution Phase 2. These are areas of research, not established clinical uses unless the compound is FDA-approved for them.

What is Survodutide?

Survodutide is classified as: GLP-1/glucagon dual agonist. Also known as: BI 456906.

Combinations to avoid

Survodutide appears in 1 flagged combination catalogued on PeptideHelper.org:

Drug class

Research focus area

All peptides studied for Metabolic & Weight, ranked by evidence tier and regulatory status.

Primary sources

  1. le Roux CW et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity — randomised, double-blind, dose-finding phase 2 trial. Lancet Diabetes Endocrinol 2024. PMID 38330987
  2. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis [NCT06632457 PHASE3 RECRUITING]
  3. Ekinci EI et al. Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity. Diabetes, obesity & metabolism 2026. PMID 42331726
  4. Almandoz JP et al. How does survodutide work? Plain language review of a potential new medication for obesity and liver disease. Therapeutic advances in gastroenterology 2026. PMID 42254697
  5. le Roux CW et al. Survodutide Once Weekly for the Treatment of Adults with Obesity. The New England journal of medicine 2026. PMID 42253238
  6. Kaplan LM et al. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nature medicine 2026. PMID 42252333
  7. Yokote K et al. Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial. Diabetes, obesity & metabolism 2026. PMID 42219222
  8. Savas M et al. Beyond weight loss: multisystem benefits of obesity medications. The lancet. Diabetes & endocrinology 2026. PMID 42208956
  9. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis [NCT06632444 PHASE3 RECRUITING]
  10. Patil R et al. Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Cirrhosis Clinical Trials: Lessons Learned and Future Directions. Drugs 2026. PMID 41831171
  11. Platz E et al. Survodutide for the Treatment of Obesity: Baseline Characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial. JACC. Heart failure 2026. PMID 41329105
  12. A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease [NCT06176365 PHASE3 COMPLETED]
  13. Ji L et al. Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE™-CN). Diabetes therapy : research, treatment and education of diabetes and related disorders 2026. PMID 42599381
  14. Bijoch J. Anti-Obesity Medications in Longevity and Aesthetic Medicine. Journal of clinical medicine 2026. PMID 42590128
  15. Noureddin M et al. Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH. Hepatology (Baltimore, Md.) 2026. PMID 42545725
  16. Puspitasari IM et al. Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review. Diabetes, metabolic syndrome and obesity : targets and therapy 2026. PMID 42812898
  17. Amjad MM et al. Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis. Diabetes, obesity & metabolism 2026. PMID 42811393
  18. Zhao Z et al. Pathogenesis-Informed Phenotype-Guided Therapy for MASH: A Three-Axis Translational Framework Within the MASLD Spectrum. Biomedicines 2026. PMID 42792628
  19. A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) [NCT06077864 PHASE3 COMPLETED]
  20. He J. Does Survodutide Provide Renoprotection Beyond Its Metabolic and Haemodynamic Effects in Diabetic Kidney Disease?. Diabetes, obesity & metabolism 2026. PMID 42864267
  21. Ard JD et al. The Power of Two: Harnessing Dual Glucagon and Incretin Signaling for Treatment of Obesity and Metabolic Dysfunction-Associated Steatohepatitis-A Narrative Review with a Translational Focus. Obesity reviews : an official journal of the International Association for the Study of Obesity 2026. PMID 42860310
  22. SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight [NCT07850050 PHASE3 NOT_YET_RECRUITING]
  23. Ye T. Interpreting Survodutide Renoprotection in a Hyperfiltration Model. Diabetes, obesity & metabolism 2026. PMID 42897119
  24. SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight [NCT07855900 PHASE3 NOT_YET_RECRUITING]
  25. A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity [NCT07768813 PHASE1 ACTIVE_NOT_RECRUITING]
  26. ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease [NCT07850063 PHASE3 NOT_YET_RECRUITING]
  27. Sanville M et al. Charcoal-Based Depletion Method to Improve Drug Tolerance in Neutralizing Antibody Assays for Therapeutic Peptides. The AAPS journal 2026. PMID 42963450
  28. Sergi CM. Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties. Contemporary clinical trials 2026. PMID 42822760
  29. Bozkurt B et al. Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet (London, England) 2026. PMID 43003106
  30. A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity [NCT06745284 PHASE1 ACTIVE_NOT_RECRUITING]
  31. A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body [NCT07407348 PHASE1 ACTIVE_NOT_RECRUITING]
  32. A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar [NCT07754461 PHASE3 RECRUITING]
  33. A Study to Compare How Survodutide is Taken up by the Body When Given in 2 Formulations to People With Overweight or Obesity [NCT07940244 PHASE1 NOT_YET_RECRUITING]

Open the full interactive PeptideHelper.org reference to compare peptides side-by-side, evaluate stacks, and explore the catalog.

Spot an error or a missing source on this page? Suggest a correction. Corrections are logged and surfaced in the next review.

Loading interactive view…